Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D51F | ISIN: CA88410L1022 | Ticker-Symbol:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
THIOGENESIS THERAPEUTICS CORP Chart 1 Jahr
5-Tage-Chart
THIOGENESIS THERAPEUTICS CORP 5-Tage-Chart

Aktuelle News zur THIOGENESIS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoThiogenesis Therapeutics Corp: Thiogenesis receives patent in Europe2
MoThiogenesis Therapeutics, Corp.: Thiogenesis Announces Important Core Patent Allowed in Europe191San Diego, California--(Newsfile Corp. - November 4, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol...
► Artikel lesen
28.09.Thiogenesis Therapeutics Corp: Thiogenesis hires Triomphe for IR services2
27.09.Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Investor Relations Engagement705San Diego, California--(Newsfile Corp. - September 27, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing thiol-active...
► Artikel lesen
17.09.Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium393San Diego, California--(Newsfile Corp. - September 17, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides...
► Artikel lesen
20.08.Thiogenesis Therapeutics Corp: Thiogenesis signs agreement with UCSD1
20.08.Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program195San Diego, California--(Newsfile Corp. - August 20, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides...
► Artikel lesen
18.07.Thiogenesis Therapeutics Corp: Thiogenesis signs research deal for its Leigh compound2
18.07.Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Leigh Syndrome Clinical Program330San Diego, California--(Newsfile Corp. - July 18, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that...
► Artikel lesen
25.03.Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS313San Diego, California--(Newsfile Corp. - March 25, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides...
► Artikel lesen
20.12.23Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement396San Diego, California--(Newsfile Corp. - December 20, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that, further to its news release...
► Artikel lesen
17.12.23Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Closing of Non-Brokered Private Placement of Common Shares and Insider Participation 205San Diego, California--(Newsfile Corp. - December 18, 2023) - Further to its news release of November 20, 2023, Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very...
► Artikel lesen
04.12.23Thiogenesis Therapeutics, Corp.: Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria Symposium604San Diego, California--(Newsfile Corp. - December 4, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company that is developing sulfur-containing...
► Artikel lesen
27.11.23Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Addition of Dr. Vince Stanton Jr. to Its Scientific Advisory Board544San Diego, California--(Newsfile Corp. - November 27, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing...
► Artikel lesen
20.11.23Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Non-Brokered Private Placement of Common Shares663San Diego, California--(Newsfile Corp. - November 20, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") announced today that it will undertake a non-brokered private...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1